patient

Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia 

Original Publication Date
Article Source
External Web Content

Post-transplant cyclophosphamide (PTCy) is associated with infectious and organ toxicities. Dose optimization may reduce these risks while maintaining efficacy. We initiated a prospective pilot study in July 2024 evaluating reduced-dose PTCy (35 mg/kg on days +3 and +4; PTCy70)…

New ASH Guidelines on Diagnosis and Management of Aplastic Anemia

Thumbnail for video Register Now

Topic(s)
Aplastic Anemia
Presenter(s)
Phil Scheinberg, MD

ASH recently released new clinical practice guidelines for the diagnosis and management of aplastic anemia for both pediatric and adult patients. In this webinar, Dr. Scheinberg will discuss the new guidelines and impact for patients. At the end of the presentation, there will be…

Akriti Jain, M.D

Institution
Cleveland Clinic
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Lymphocytic Leukemia (CLL)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About

Akriti G Jain, MD treats myeloid disorders at Cleveland Clinic’s Main Campus in Cleveland, Ohio. She has a personal interest in taking care of patients with Myeloproliferative Neoplasms including Chronic Myeloid Leukemia. Her passion lies in understanding the needs of every patient and always prioritizing and advocating for her patients and their families. Her patient care philosophy involves offering in-depth explanation regarding diagnoses and to engage in active partnership with her patients and their referring providers to personalize decision-making and monitoring given the nature of the

Rory Shallis, MD

Institution
Moffit Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
About

Dr. Shallis received his MD from Rutgers-Robert Wood Johnson Medical School, completed his residency training at Brown University-Rhode Island Hospital and fellowship training at Yale-New Haven Hospital. He is focused on the care and research of patients with myeloid malignancies, particularly acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). He also participated in the K12 Calabresi Immuno-Oncology Training Program and currently participates as an investigator in several clinical trials aimed at improving the outcomes of patients with AML and MDS. Dr. Shallis also maintains

Subscribe to patient

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.